Clinical Trials, Phase II as Topic
"Clinical Trials, Phase II as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.
| Descriptor ID |
D017322
|
| MeSH Number(s) |
E05.318.760.250.500.210 N05.715.360.775.088.500.210 N06.850.520.450.250.250.210
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase II as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase II as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase II as Topic" by people in this website by year, and whether "Clinical Trials, Phase II as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 2 | 3 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 3 | 4 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 3 | 4 |
| 2014 | 0 | 3 | 3 |
| 2016 | 1 | 6 | 7 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 8 | 9 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 4 | 4 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clinical Trials, Phase II as Topic" by people in Profiles.
-
Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy. BMC Cancer. 2024 Dec 04; 24(1):1493.
-
Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety. Cancer. 2025 Jan 01; 131(1):e35661.
-
Bayesian Safety and Futility Monitoring in Phase II Trials Using One Utility-Based Rule. Stat Med. 2024 Dec 20; 43(29):5583-5595.
-
TGF-? trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance. J Immunother Cancer. 2024 Oct 26; 12(10).
-
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer. J Immunother Cancer. 2024 Oct 20; 12(10).
-
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II?trial. Future Oncol. 2024; 20(38):3065-3075.
-
A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer. Future Oncol. 2024; 20(31):2319-2329.
-
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer. Future Oncol. 2024; 20(36):2811-2822.
-
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. Acta Haematol. 2025; 148(2):180-197.
-
COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC. Future Oncol. 2024; 20(30):2241-2248.